TriangleBinimetinib (NCT04598009)
Binimetinib trial for Melanoma Stage III (NCT04598009). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable stage III or IV KIT-mutated melanoma not suitable for local treatment. Standard therapy must have failed, be unsuitable, or be intolerable.
The idea: binimetinib blocks MEK signaling; imatinib blocks KIT and other growth-related kinases. Both are taken orally, binimetinib twice daily and imatinib once daily, in 28-day cycles. Researchers measure tumor responses, safety, and resistance mechanisms. Measurable disease and confirmation of the KIT mutation are required.
This phase 2 study plans 25 patients. Katy Tsai leads at UCSF; San Francisco and La Jolla sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.